San Diego-centered Viking Therapeutics marked alone as a serious competitor within the weight loss drug sector in February just after revealing promising knowledge from the mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered as a weekly injection As well as in March the com